Tru-D SmartUVC, a leader in the UVC disinfection industry, will attend and exhibit at APIC 2018, June 13-15 in Minneapolis, Minnesota, sharing infection prevention data. Each year, APIC delivers the largest annual conference of infection preventionists from across the U.S., and Tru-D invites attendees to stop by its booth #621.

A recent study published in The Lancet Infectious Diseases, discusses the prescribed secondary analysis of the BETR-D randomized clinical trial, for which Tru-D was the only device chosen. The study authors sought to prove that a measured dose of UV disinfection in targeted, at-risk rooms would have both direct effects on the next patient who entered the room and an indirect effect on all hospitalized patients, leading to a hospital-wide decreased risk of target organisms. Following the two-year, $2 million, CDC-funded trial, the researchers concluded that, “Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms led to a decrease in hospital-wide incidence of C. difficile and VRE.”

“This study is the first to prove that not only is UV disinfection effective at reducing the risk of infection for the next patient who enters a room that was previously occupied by an infected patient, but that it can also reduce infections throughout the entire facility,” said Alice Brewer, MPH, CIC, Director of Clinical Affairs for Tru-D SmartUVC.

For more information and links to independent studies, visit Tru-D.com.